Author(s)

Yanjie Sun

Corresponding Author

Yanjie Sun

ABSTRACT

A recent retrospective study found that the prognosis of some patients with relapsed/refractory DLBCL was poor. Its results indicate the emergent requirement for a new treatment. This review focused on the structure of loncastuximab tesirine and its mechanism, as well as phase I and phase II experimental studies in non-Hodgkin's lymphoma. The safety and efficacy of loncastuximab tesirine in DLBCL were analyzed. Efficacy data showed that loncastuximab tesirine was active in different types of non-Hodgkin's lymphoma, and phase II studies showed persistent responses, including high-risk subgroups. Loncastuximab tesirine will be an important supplement to the alternative therapy of DLBCL.

KEYWORDS

Loncastuximab tesirine, DLBCL, cancer, immunological therapy